文献速递眼整形与眼眶眼底病与葡萄膜炎

IgG4阳性眼附属器结外边缘区淋巴瘤更具侵袭性:377例队列证据

IgG4-Positive Ocular Adnexal Extranodal Marginal Zone Lymphoma as an Aggressive Clinical Subtype: Evidence From a 377-Patient Cohort.
PubMed 文献 · Am J Ophthalmol · 2026-01-27

IgG4阳性在结外边缘区淋巴瘤(EMZL)中占比最高(23.3%),表现为更广泛局部累及、更高Ki-67指数、更早复发及更高复发风险。

要点

  • IgG4阳性EMZL患者T3-T4期比例更高、局部累及范围更广。
  • IgG4阳性EMZL患者Ki-67指数更高(20.08±6.56 vs 14.13±5.03)。
  • IgG4阳性EMZL患者复发更早且累积无复发比例更低。

核心结论

  • IgG4阳性EMZL是更具侵袭性的临床亚型,表现为更广泛局部累及和更高复发风险,需更强化管理和长期随访。

主要发现

  • IgG4阳性比例最高见于EMZL(23.3%[75/322]),且眼睑、泪腺、视神经、眶上/下裂、海绵窦及颞下窝/翼腭窝受累频率显著高于IgG4阴性EMZL。
  • IgG4阳性EMZL患者就诊时T3-T4期更常见,全身受累差异经Benjamini-Hochberg校正后无统计学意义。
  • IgG4阳性EMZL患者Ki-67指数更高(20.08±6.56 vs 14.13±5.03,P<.0001),IgG4阳性浆细胞与T分期及Ki-67指数显著正相关。
  • IgG4阳性与阴性EMZL患者均以手术后放疗为主,但IgG4阳性患者复发更早(2.04±1.21年 vs 3.71±1.23年,P=.002)且累积无复发或再手术比例更低(All P<.01)。
  • 多因素Cox回归显示IgG4阳性EMZL与复发强相关(HR,2.04,95%CI,1.07-3.91,P=.031),组织IgG4阳性浆细胞与复发时间显著负相关(rs=-0.605,P<.0001)。

关键数值与推荐

  • IgG4阳性在EMZL中占比23.3%(75/322)。
  • IgG4阳性EMZL患者Ki-67指数为20.08±6.56,IgG4阴性为14.13±5.03(P<.0001)。
  • IgG4阳性EMZL复发时间为2.04±1.21年,IgG4阴性为3.71±1.23年(P=.002)。
  • 多因素Cox回归HR为2.04(95%CI,1.07-3.91,P=.031)。
  • 组织IgG4阳性浆细胞与复发时间相关系数rs=-0.605(P<.0001)。

临床怎么用

  • 对IgG4阳性EMZL患者应视为更具侵袭性亚型,考虑更密集的治疗和长期随访监测。
  • 需建立针对IgG4阳性EMZL的靶向管理策略以优化疾病控制。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To investigate the clinicopathological characteristics of IgG4-positive ocular adnexal lymphoma (OAL). DESIGN: Retrospective clinical cohort study. PARTICIPANTS: A total of 377 patients diagnosed with OAL between October 2014 and October 2024 were enrolled. Study data were analyzed from March 2025 to August 2025. METHODS: A comprehensive review of the medical records for all OAL patients was conducted. The distribution of IgG4-positive cases was assessed. Clinicopathological characteristics, as well as recurrence risk, were compared between IgG4-positive and IgG4-negative patients. MAIN OUTCOMES AND MEASURES: Differences in local and systemic involvement at baseline, and recurrence risk during follow-up. RESULTS: The highest proportion of IgG4-positive patients was observed in extranodal marginal zone lymphoma (EMZL) (23.3% [75/322]), with a significant higher frequency of involvement in the eyelid, lacrimal gland, optic nerve, superior/inferior orbital fissures, cavernous sinus, and Infratemporal fossa/pterygopalatine fossa compared with IgG4-negative EMZL patients. At presentation, T3-T4 stages were more frequently observed among IgG4-positive EMZL patients, while differences in systemic involvement showed no statistical significance after Benjamini-Hochberg adjustment. The Ki-67 index was higher in IgG4-positive EMZL patients (20.08 ± 6.56 vs 14.13 ± 5.03, P < .0001), and IgG4-positive plasma cells showed significant positive correlations with T-stage and Ki-67 index. Both IgG4-positive and IgG4-negative EMZL patients were primarily treated with radiotherapy following surgery. IgG4-positive EMZL patients experienced earlier recurrence (2.04 ± 1.21 years vs 3.71 ± 1.23 years, P = .002) and a lower cumulative proportion without recurrence or reoperation (All P < .01). Cox regression analysis revealed a strong association between IgG4-positive EMZL and recurrence in multivariate model (HR, 2.04, 95% CI, 1.07-3.91, P = .031). IgG4-positive plasma cells in tissue were significantly negatively correlated with the time to recurrence (rs = -0.605, P < .0001). CONCLUSIONS: IgG4-positive EMZL represents a more aggressive clinical subtype, characterized by more widespread local involvement and an increased risk of recurrence, thereby warranting more intensive management and long-term follow-up for disease surveillance. Targeted management strategies need to be established to achieve optimal disease control.

来源:Am J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Sun H, Tang J, Li J, et al. IgG4-Positive Ocular Adnexal Extranodal Marginal Zone Lymphoma as an Aggressive Clinical Subtype: Evidence From a 377-Patient Cohort. Am J Ophthalmol. 2026. PMID: 41611000. doi:10.1016/j.ajo.2026.01.030

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。